Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigious | ||
Readability |
H.S. freshman Good
|
Filing tables
Filing exhibits
- 10-K Annual report
- 10.4 EX-10.4 Amend. NO.1 to the 2004 Stock Incentive Plan
- 10.19 EX-10.19 Approval Agreement Dated 3/7/06 with H. Shaw Warren, JR. MD
- 10.20 EX-10.20 Approval Agreement Dated 3/7/06 with Kevin J. Tracey, MD
- 10.24 EX-10.24 the Fourth Loan Modification Agreement Dated January 6, 2006
- 10.49 EX-10.49 Non-employee Director Compensation and Reimbursement Policy
- 10.50 EX-10.50 Amend. NO.1 to the Medimmune Exclusive License and Collaboration Agreement
- 10.51 EX-10.51 Critical Therapeutics, Inc. 2006 Company Goals
- 10.52 EX-10.52 Critical Therapeutics, Inc. 2005 Cash Bonuses for Executive Officers
- 10.53 EX-10.53 Critical Therapeutics, Inc. 2006 Salaries for Executive Officers
- 10.54 EX-10.54 Maximum Annual Cash Bonuses for Executive Officers
- 21.1 EX-21.1 Subsidiaries of the Registrant
- 23.2 EX-23.2 Consent of Deloitte & Touche LLP
- 31.1 EX-31.1 Section 302 Certification of CEO
- 31.2 EX-31.2 Section 302 Certification of CFO
- 32.1 EX-32.1 Section 906 Certification of CEO
- 32.2 EX-32.2 Section 906 Certification of CFO
Related press release
CRTX similar filings
External links